Uroplasty Reports Record Quarterly Revenue

~ U.S. Urgent PC Sales Up 19% in Fiscal Third Quarter

~~ Total Sales Increase by 14% to $6.4 Million

Jan 23, 2014, 16:01 ET from Uroplasty, Inc.

MINNEAPOLIS, Jan. 23, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported strong financial results for the fiscal 2014 third quarter ended December 31, 2013. 

Total revenues for the fiscal third quarter 2014 were $6.4 million, up 14% from the same quarter in the prior year. Sales of the Company's Urgent® PC Neuromodulation System in the United States grew 19% to $3.2 million, as compared to $2.7 million in the third quarter of the prior year.  Sales of Macroplastique in the United States grew 11% to $1.5 million in the third quarter of fiscal 2014.  Total net sales outside of the U.S. grew 11% to $1.6 million.

"Successful execution of the sales strategies we implemented earlier this fiscal year drove our continued sequential and year-over-year improvement," said Rob Kill, President and Chief Executive Officer of Uroplasty.  "We are encouraged with the growth results generated to date for U.S. Urgent PC sales and expect recent trends to continue during the fourth quarter.  Our sales force is gaining momentum following our investment in ongoing training during the third quarter and, as a result, we are forecasting 25-30% year-over-year revenue growth for Urgent PC in the U.S. for the fourth quarter of fiscal 2014." 

The Company generated a gross margin of 87.8% in the recent fiscal third quarter compared with 86.9% in the same quarter a year ago.  Operating expenses for the period totaled $6.3 million compared to $5.5 million in the same quarter last year.  The increase was due primarily to higher sales and marketing costs reflecting higher personnel expenses resulting from the expansion and reorganization of the Company's selling and marketing team, costs for increased marketing programs, and the  new medical device tax.

The operating loss of $0.7 million in the fiscal third quarter compares with a $0.7 million operating loss in the same quarter last year.  Excluding non-cash charges for share-based compensation and depreciation and amortization expense, the non-GAAP operating loss was $0.3 million in the third quarter of fiscal 2014, compared with a $0.1 million non-GAAP operating loss in the third quarter a year ago. 

For the nine-month period ended December 31, 2013, sales grew 8% to $18.2 million, reflecting a 9% increase in U.S. sales and a 5% increase in sales outside the U.S. In the U.S., sales of Urgent PC increased 13% to $9.0 million.  At December 31, 2103, cash, cash equivalents and cash investments totaled $12.6 million.

Conference Call Uroplasty will host a conference call and webcast today at 4:30 p.m. Eastern Time (3:30 p.m. Central Time) to discuss these results. Rob Kill, President and Chief Executive Officer, and Brett Reynolds, Chief Financial Officer, will host the call. Individuals wishing to participate in the conference call should dial 877-941-9205. No passcode is necessary.  To access a live webcast of the call, go to Uroplasty's website at www.uroplasty.com and click on the Investor Relations section.

An audio replay will be available for 30 days following the call at 800-406-7325 with the passcode 4660925#.  An archived webcast will also be available at investor.uroplasty.com.

About Uroplasty, Inc. Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical company committed to offering transformative treatment options to specialty physicians.  Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only commercially available FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

Forward-Looking Information This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results. We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.  In particular, we cannot be certain that we will ever achieve sustained profitability, that the rate of reimbursement for PTNS treatments will be adequate to justify the cost of our product, that other Medicare carriers or private payers will provide coverage for this treatment or that existing carriers and payers will not change their coverage decisions, that the rate of adoption of our products by new customers will continue, or that any of the other risks identified in our 10-K will not adversely affect our expectations as described in these forward-looking statements.

For Further Information: Uroplasty, Inc. Brett Reynolds, SVP and CFO 952.426.6152

EVC Group Leigh Salvo (Investors) 415.568.9348 or Doug Sherk 415.652.9100 Janine McCargo (Media) 646.688.0425

           

UROPLASTY, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended

Nine Months Ended

December 31

December 31

2013

2012

2013

2012

Net sales

$6,398,675

$5,590,431

$18,216,391

$16,877,394

Cost of goods sold

$778,267

734,171

2,268,156

2,264,721

Gross profit

5,620,408

4,856,260

15,948,235

14,612,673

Operating expenses

General and administrative

1,194,882

1,058,558

5,166,255

3,178,239

Research and development

526,224

533,867

1,434,647

1,695,841

Selling and marketing

4,546,100

3,725,530

13,496,593

11,424,407

Amortization

7,873

215,681

22,347

646,971

6,275,079

5,533,636

20,119,842

16,945,458

Operating loss

(654,671)

(677,376)

(4,171,607)

(2,332,785)

Other income (expense)

Interest income

3,836

12,327

18,576

35,836

Interest expense

-

(12)

-

(12)

Foreign currency exchange gain (loss)

(506)

445

(4,540)

(3,432)

3,330

12,760

14,036

32,392

Loss before income taxes

(651,341)

(664,616)

(4,157,571)

(2,300,393)

Income tax expense

19,491

12,708

50,033

35,812

Net loss

$(670,832)

$(677,324)

$(4,207,604)

$(2,336,205)

Basic and diluted net loss per common share

$(0.03)

$(0.03)

$(0.20)

$(0.11)

Weighted average common shares outstanding:

Basic and diluted

21,258,736

20,798,997

21,035,874

20,768,632

 

 

UROPLASTY, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

December 31, 2013

March 31, 2013

Assets

       Current assets:

           Cash and cash equivalents

$8,164,251

$3,533,864

           Short-term investments

4,452,234

7,936,605

           Accounts receivable, net

2,534,929

2,553,447

           Inventories

469,094

718,933

           Other

554,412

566,536

       Total current assets

16,174,920

15,309,385

       Property, plant and equipment, net

1,051,857

1,033,085

       Intangible assets, net

119,455

100,502

       Long-term investments

-

3,451,711

       Deferred tax assets

153,347

146,052

       Total assets

$ 17,499,579

$20,040,735

Liabilities and Shareholders' Equity

       Current liabilities:

           Accounts payable

$645,170

$618,916

           Current portion – deferred rent

12,351

35,000

           Income tax payable

18,242

7,729

           Accrued liabilities:

               Compensation

1,836,589

1,550,846

               Other

354,719

476,287

       Total current liabilities

2,867,071

2,688,778

       Deferred rent – less current portion

-

5,141

       Accrued pension liability

666,818

660,580

       Total liabilities

3,533,889

3,354,499

       Total shareholders' equity

13,965,690

16,686,236

       Total liabilities and shareholders' equity

$17,499,579

$20,040,735

 

 

UROPLASTY, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Nine Months Ended

December 31

2013

2012

Cash flows from operating activities:

Net loss

$(4,207,604)

$(2,336,205)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

267,369

864,227

(Gain) loss on disposal of equipment

(5,000)

3,035

Amortization of premium on marketable securities

7,562

39,551

Share-based consulting expense

-

1,623

Share-based compensation expense

1,210,201

608,953

Deferred income tax expense

3,245

5,473

Deferred rent

(27,790)

(27,638)

Changes in operating assets and liabilities:

Accounts receivable, net

79,428

228,768

Inventories

255,207

(138,862)

Other current assets

16,868

(70,401)

Accounts payable

21,724

(82,514)

Accrued compensation

274,139

199,936

Accrued liabilities, other

(120,881)

67,147

Accrued pension liability, net

(39,011)

5,074

Net cash used in operating activities

(2,264,543)

(631,833)

Cash flows from investing activities:

Proceeds from maturity of available-for-sale investments

2,750,000

3,200,000

Proceeds from maturity of held-to-maturity investments

4,180,000

5,000,000

Purchases of available-for-sale investments

-

(4,921,036)

Purchases of held-to-maturity investments

-

(2,500,000)

Purchases of property, plant and equipment

(221,769)

(137,101)

Proceeds from sale of property, plant and equipment

6,773

7,038

Payments for intangible assets

(41,300)

(4,440)

Net cash provided by investing activities

6,673,704

644,461

Cash flows from financing activities:

Proceeds from exercise of options

172,485

150,000

Net cash provided by financing activities

172,485

150,000

Effect of exchange rate changes on cash and cash equivalents

48,741

(6,313)

Net increase in cash and cash equivalents

4,630,387

156,315

Cash and cash equivalents at beginning of period

3,533,864

4,653,226

Cash and cash equivalents at end of period

$8,164,251

$4,809,541

Non-GAAP Financial Measures:  The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (GAAP) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, depreciation and amortization expenses from gross profit, operating expenses and operating loss.  The non-GAAP financial measures used by management and disclosed by us are not a substitute for, nor superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP.  We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies.  Therefore, our non-GAAP financial measures may not be comparable to those used by other companies.  We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.

We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes because we believe such measures are important indicators of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss during the three months ended December 31, 2013 and 2012 was approximately $277,000 and $135,000, respectively.  The increase in non-GAAP operating loss for the three months ended December 31, 2013 over the corresponding period a year ago is attributed to the increase in operating spending, offset slightly by the increase in net sales and gross profit percent.  Our non-GAAP operating loss during the nine months ended December 31, 2013 and 2012 was approximately $2.7 million and $858,000, respectively.  The increase in non-GAAP operating loss for the nine months ended December 31, 2013 over the corresponding period a year ago is attributed to the increase in operating spending (including $1.4 million of cash costs related to our review of internal control over financial reporting and executive management changes), offset slightly by the increase in net sales and gross profit percent.

Expense Adjustments

Three-Months Ended

GAAP

Share-based   Expense

Depreciation

Amortization of Intangibles

Non-GAAP

December 31, 2013

Gross profit

$5,620,000

$6,000

$8,000

$5,634,000

% of net sales

87.8%

88.1%

Operating expenses

    General and administrative

1,195,000

(197,000)

(50,000)

948,000

    Research and development

526,000

(11,000)

(1,000)

514,000

    Selling and marketing

4,546,000

(75,000)

(22,000)

4,449,000

    Amortization

8,000

(8,000)

-

6,275,000

(283,000)

(73,000)

(8,000)

5,911,000

Operating loss

$(655,000)

$289,000

$81,000

$8,000

$(277,000)

December 31, 2012

Gross profit

$4,856,000

$8,000

$8,000

$4,872,000

% of net sales

86.9%

87.2%

Operating expenses

    General and administrative

1,059,000

(146,000)

(50,000)

863,000

    Research and development

534,000

(14,000)

(1,000)

519,000

    Selling and marketing

3,725,000

(87,000)

(13,000)

3,625,000

    Amortization

216,000

$(216,000)

-

5,534,000

(247,000)

(64,000)

(216,000)

5,007,000

Operating loss

$(678,000)

$255,000

$72,000

$216,000

$(135,000)

Expense Adjustments

Nine-Months Ended

GAAP

Share-based Expense

Depreciation

Amortization of Intangibles

Non-GAAP

December 31, 2013

Gross profit

$15,948,000

$20,000

$26,000

$15,994,000

% of net sales

87.5%

87.8%

Operating expenses

    General and administrative

5,166,000

(952,000)

(153,000)

4,061,000

    Research and development

1,435,000

(36,000)

(3,000)

1,396,000

    Selling and marketing

13,497,000

(202,000)

(63,000)

13,232,000

    Amortization

22,000

$(22,000)

-

20,120,000

(1,190,000)

(219,000)

(22,000)

18,689,000

Operating loss

$(4,172,000)

$1,210,000

$245,000

$22,000

$(2,695,000)

December 31, 2012

Gross profit

$14,613,000

$23,000

$26,000

$14,662,000

% of net sales

86.6%

86.9%

Operating expenses

    General and administrative

3,178,000

(340,000)

(146,000)

2,692,000

    Research and development

1,696,000

(40,000)

(2,000)

1,654,000

    Selling and marketing

11,425,000

(208,000)

(43,000)

11,174,000

    Amortization

647,000

$(647,000)

-

16,946,000

(588,000)

(191,000)

(647,000)

15,520,000

Operating loss

$(2,333,000)

$611,000

$217,000

$647,000

$(858,000)

SOURCE Uroplasty, Inc.



RELATED LINKS

http://www.uroplasty.com